🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In #DICTATE trial, dapagliflozin was safe to start first day of AHF hospitalization before stabilization to optimize #GDMT & improve some measures of diuresis. #SGLT2i should be started immediately or continued in most pts hospitalized for AHF bit.ly/3VK4fmK #JACC Zachary Cox

Here we go again! Want to see if the coronary sinus reducer works in refractory angina? Watch Michael Foley present the results of the ORBITA-COSMIC in the main arena at #ACC this Monday #ORBITA Fiyyaz Ahmed-Jushuf Matthew Shun-Shin Shayna Chotai Christopher Rajkumar Florentina Simader

Thank you for joining us at Minneapolis Heart Institute Foundation for the 1st US meeting on CT-guided PCI! We had an incredible 1.5 days with outstanding lectures, hands-on sessions, & live cases addressing #CT4PCI. Huge thanks to our faculty speakers, participants, & sponsors for making this event a

Why does treating #TR improve dyspnoea? Find out more on the importance and effects of #TTEER on left 🫀 #hemodynamics and #HeartFailure onlinelibrary.wiley.com/doi/10.1002/ej… Karl-Philipp Rommel Philipp Lurz Holger Thiele @A_Schoeber Sebastian Rosch Patrick Sullivan Marco Metra Frederik H. Verbrugge a 🧵1/6

New CarDS Lab #echofirst paper out in JAMA Cardiology #ACC24 We build on our recent work on detecting AS from 2D echo w/o Doppler using a video-based AI biomarker (DASSi, ref: tinyurl.com/hrupxwbv) ✅DASSi stratifies the risk of AS progression among more than 12k participants

Philippe Rola Ramanathan KR Matt Siuba Ross Prager IMCrit Graeme MacLaren Ritu Thamman MD ABCDEcografía Pulmonary-POCUS korbinhaycockmd NephroPOCUS 7/ 🔆 How to treat RVOTO? ♦️ Detect EARLY !! ♦️ Mechanical causes: - Surgery ♦️Dynamic causes: - Adequate preload - Inotropes withdrawal - Beta-blockers or CCBs

After 10 years to complete it, the DanGer-SHOCK trial showed that the routine use of a microaxial flow pump with standard care in the treatment of patients with STEMI-related cardiogenic shock led to a lower risk of death from any cause at 180 days than standard care alone. The

I’m honored to join this amazing team! Look forward to contributing the advancement of this field☺️ Minneapolis Heart Institute Foundation Dr. Gilbert Tang Dee Dee Wang MD Hasan Jilaihawi Syed Zaid, MD

Does age impact the optimal testing strategy for stable patients with suspected CAD? Yale Internal Medicine star Evangelia Vemmou presenting her work from PRECISE!

Amazing to see a brilliant friend and colleague Michael Foley present the #ORBITA-COSMIC trial of the coronary sinus reducer with simultaneous publication in The Lancet Rasha Al-Lamee NHLI Imperial NHS 💙 #ACC2024 thelancet.com/journals/lance…

Over the last three days, we’ve seen almost all pharmacological strategies presented at #ACC24 fail, including beta blockers, which seemed like the only certainty. On the contrary, if we are to believe in the results we've seen, we should start using more microaxial flow pump

The PREVENT trial showed that preventive #PCI of focal non-FFR-positive plaques that are angiographically >50% & have evidence of vulnerability on intravascular imaging along w/ OMT is superior to OMT for clinical outcomes at 2 years. Read more: bit.ly/3xuHWrl #ACC24

To screen or not to screen for #ASCVD with cancer treatment? Historic #ACC24 moments with phenomenal cases and debates on all questions #CardioOnc. Kudos Giselle A. Suero Abreu, MD PhD Tochi Okwuosa #GlobalEquityinHealth #CardioOnc Eric H Yang, MD Juan Lopez-Mattei, MD

Couldn’t be prouder of Michael Foley and the ORBITA team today. What are the chances that ORBITA-COSMIC would be published on the same day as a solar eclipse?!

Patients w/ #CCD who were younger or had a high burden of angina derived ⬆️ symptomatic benefit from invasive management Models to predict a patient's 1-yr health status outcomes w/ different Tx strategies could be used to inform shared decision-making bit.ly/43VdLpt

Results of this cohort study show that large TET2 and ASXL1 CHIP—but not DNMT3A CHIP—were associated with higher IL-6 level, indices of cardiac remodeling, and an increased risk for AF. ja.ma/3VOzLAf

We are thrilled to announce the Minneapolis Heart Institute Foundation CT for PCI 2.0 course on Oct 24-25, 2024! 1.5 days of lectures & discussions, hands-on training, & live cases. Limited open registration: bit.ly/3zXGZZy Join us to discuss & learn together about #CT4PCI Center for Coronary Artery Disease Emmanouil Brilakis

The game just changed in cardiology! 🫀 Coronary CT #CCTA can now assess coronary microvascular dysfunction – a huge leap forward in diagnosing and treating microvascular disease. 🌟 This could reshape how we approach #CMD 🔥Just published JACC Journals sciencedirect.com/science/articl…

Just 10 days left until our CT for PCI Course 2.0! We’re thrilled to host this event for the second time this year. 📅 October 24-25, 2024 | Minneapolis, MN Meet the Course Directors: @YaderSandoval João Cavalcante @Esbrilakis Carlos Collet MD PhD Minneapolis Heart Institute Foundation SCAI #CT4PCI

#TCT2024: In #JACC, Koshiro Sakai, MD PhD, Ziad Ali, and team report that photon-counting CT imaging ⬆️ diagnostic performance for obstructive CAD compared with conventional CT bit.ly/3UnSEsg #cvCAD #cvImaging #CardioX